Openbookopenbook
Equity
Ono Pharmaceutical Co Ltd(OPHLY)
USD --+0.00%
Reward57Moderate
Risk13Low
📊75%Data
3.1% dividend yield
OPHLY
+0.0 · +0.00%
USD · PINK
Ono Pharmaceutical Co Ltd | Healthcare
Deep Value
Market Cap:8.00Bn
ℹ️
Reward Rating
57
Moderate
Top 50% (model universe)
75% data coverage
ℹ️
Risk Rating
13
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on OPHLY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Ono Pharmaceutical Co Ltd?

produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide.

OPHLY · Verdict

Solid reward · low risk

OPHLY stands out on volatility and balance sheet, but watch the growth signal.

Based on 88% data coverage

OPHLY · Verdict

What’s working & what to watch

Strengths 5

  • Volatility95/100

    Top decile vs peers

  • Balance sheet92/100

    Interest covered 12.2×

  • Valuation91/100

    P/E 13.6×

  • Cash flow81/100

    15% free-cash-flow margin

  • Profitability65/100

    10% net margin · 8% ROE

Watchouts 1

  • Growth45/100

    Rev +10.4% CAGR · earnings -14.7%

Model-based scoring. For information only — not financial advice.

What is Ono Pharmaceutical Co Ltd?

produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.00B, and a P/E ratio of 23.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (57)

The scoring profile indicates moderate reward potential, with valuation and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap8.00B
P/E Ratio23.4167
Dividend Yield3.15%
52 Week High5.75
52 Week Low3.3167
Last AnnualMarch
IPO DateN/A
IncorporatedUSA
Shares Outstanding1B
No. of Employees4,287
IndustryDrug Manufacturers - General
ExchangePINK
Beta0.044
CurrencyUSD · Reports in JPY
Websitewww.ono-pharma.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.